Saudi Arabia inks MoU to boost localization of pharmaceutical industries

25/07/2019 Argaam

 

The Saudi Arabian General Investment Authority (SAGIA) has signed a memorandum of understanding (MoU) with GlaxoSmithKline Saudi Arabia (GSK) to boost localization of pharmaceutical industries across the Kingdom.

 

Under the preliminary agreement, GSK will expand the local manufacturing capacity of its pharmaceutical portfolio and double operations by 2022, the Saudi Press Agency reported.

 

GSK will also explore additional opportunities for technology transfer, and attract more Saudi employees and local capabilities.

 

GSK has been operating in Saudi Arabia for more than 65 years and was the first multinational pharmaceutical company to establish a manufacturing facility in the Kingdom in 1992.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.